Cannabinoids Show Promise Against Cervical Cancer, Especially With Nanotechnology Delivery

THC and CBD demonstrate anticancer effects in cervical cancer cells by inducing apoptosis, inhibiting proliferation, suppressing metastasis, promoting oxidative stress, and modulating immune responses. Combining cannabinoids with chemotherapy, radiotherapy, or immunotherapy enhanced efficacy and reduced drug resistance. Nanoparticle delivery systems improved targeting, solubility, and reduced systemic toxicity.

Critical synthesis of preclinical studies examining cannabinoid anticancer properties in cervical cancer, including combination therapy approaches and nanotechnology-based delivery platforms.

Cervical cancer remains a major health challenge, particularly in sub-Saharan Africa. Cannabinoids represent a new class of potential therapeutic agents, and nanotechnology may solve key delivery challenges that have limited their clinical application.

The convergence of cannabinoid research with nanotechnology and combination therapy represents a new frontier in cancer treatment. If these preclinical findings translate clinically, cannabinoid-based nanoformulations could complement existing cervical cancer treatments.

All evidence is preclinical. No human clinical trials for cannabinoids in cervical cancer exist. Optimal formulations, doses, and delivery routes remain to be determined. Regulatory challenges for cannabinoid-based medicines persist.